Stockreport

CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference [Yahoo! Finance]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF primary endpoint of fungal-free survival at day 90, and management emphasizes potential differentiation on tolerability and discontinuation versus azole-based standard c [Read more]